Egetis Therapeutics AB (publ)
STO:EGTX

Watchlist Manager
Egetis Therapeutics AB (publ) Logo
Egetis Therapeutics AB (publ)
STO:EGTX
Watchlist
Price: 6.65 SEK 0.91%
Market Cap: 2.4B SEK
Have any thoughts about
Egetis Therapeutics AB (publ)?
Write Note

Wall Street
Price Targets

EGTX Price Targets Summary
Egetis Therapeutics AB (publ)

Wall Street analysts forecast EGTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EGTX is 13.39 SEK with a low forecast of 10.1 SEK and a high forecast of 17.75 SEK.

Lowest
Price Target
10.1 SEK
52% Upside
Average
Price Target
13.39 SEK
101% Upside
Highest
Price Target
17.75 SEK
167% Upside
Egetis Therapeutics AB (publ) Competitors:
Price Targets
CTMX
CytomX Therapeutics Inc
404% Upside
SIGHT
Gensight Biologics SA
43% Upside
MOLN
Molecular Partners AG
131% Upside
214450
PharmaResearch Co Ltd
8% Upside
TNGX
Tango Therapeutics Inc
286% Upside
TWST
Twist Bioscience Corp
13% Upside
FYB
Formycon AG
77% Upside
VRDN
Viridian Therapeutics Inc
114% Upside

Revenue
Forecast

Revenue Estimate
Egetis Therapeutics AB (publ)

The compound annual growth rate of Egetis Therapeutics AB (publ)'s revenue for the next 3 years is 124%.

N/A
Past Growth
124%
Estimated Growth
Estimates Accuracy
33%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Egetis Therapeutics AB (publ)

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

Net Income Estimate
Egetis Therapeutics AB (publ)

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-57%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EGTX's stock price target?
Price Target
13.39 SEK

According to Wall Street analysts, the average 1-year price target for EGTX is 13.39 SEK with a low forecast of 10.1 SEK and a high forecast of 17.75 SEK.

What is Egetis Therapeutics AB (publ)'s Revenue forecast?
Projected CAGR
124%

The compound annual growth rate of Egetis Therapeutics AB (publ)'s revenue for the next 3 years is 124%.

Back to Top